ANDA 208202, held by Alembic. Vilazodone Hydrochloride.
As of Nov 16, 2026, ANDA 208202 (Vilazodone Hydrochloride), held by Alembic, was first approved by FDA on Jan 10, 2020, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 10, 2020 | Original application | Approved | None posted |
| Vilazodone Hydrochloride10MG · tablet;oral | Vilazodone Hydrochloride | Rx |
| Vilazodone Hydrochloride20MG · tablet;oral | Vilazodone Hydrochloride | Rx |
| Vilazodone Hydrochloride40MG · tablet;oral | Vilazodone Hydrochloride | Rx |
| May 29, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jan 3, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 18, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 18, 2023 | Supplement 2Manufacturing · Standard review | Approved | None posted |
| Jul 18, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 10, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters